Economic drug evaluation: Experiences and pathways to progress;Evaluación económica de medicamentos: Experiencias y vías de avance

Gaceta Sanitaria

Volumn 22, Issue 4, 2008, Pages 354-357

  Sacristán, José Antonio ^a,d   Dilla, Tatiana ^a   Pinto, José Luis ^b   Antoñanzas, Fernando ^c  

^a DCRandT   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^c UNIVERSITY OF LA RIOJA   (Spain)

^d ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48349086467     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1157/13125358     Document Type: Article

References (27)

1. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (version 4.1). Canberra: Department of Health and Ageing, Australian Government, 2006 [citado 16 julio 2007]. Disponible en: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbacguidelines-index
2. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd. edition. Ottawa: The Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997 [citado 16 Jul 2007]. Disponible en: http://www.cadth.ca/index.php/en/publication/35
3. National Institute for Health and Clinical Excellence (NICE). London: National Health Service [citado 16 Jul 2007]. Disponible en: http://www.nice.org.uk/
4. Drummond M, Sculpher M. Better analysis for better decisions: has pharmacoeconomics come of age? Pharmacoeconomics. 2006;24:107-8.
5. Social value judgements. Principles for the development of NICE guidance. London: NICE, 2005 [citado 16 Jul 2007]. Disponible en: http://www.nice.org.uk/ page.aspx?o=283494
6. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224-7.
7. NICE Citizens Council. Report of the first meeting: Determining clinical need. London: NICE, 2003 [citado 16 Jul 2007]. Disponible en: http://www.nice.org.uk/pdf/FINALNICEFirst-Meeting_FINALReport.pdf
8. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ. 2001;323:1300-3.
9. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-52.
10. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329:972-5.
11. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ. 2002;166:44-7.
12. Sheldon TA, Smith PC. Equity in the allocation of health care resources. Health Econ. 2000;9:571-4.
13. Peacock S, Ruta D, Mitton C, Donaldson C, Bate A, Murtagh M. Using economics to set pragmatic and ethical priorities. BMJ. 2006;332:482-5.
14. Kulp W, Greiner W, Von der Schulenburg JM. The fourth hurdle as controlling instrument for expenditure on medication? Eur J Health Econ. 2003;4:1-5.
15. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000;19:92-109.
16. Lasagna L. Clinical pharmacology: past, present and future. Lectio del Profesor Louis Lasagna en la Universidad de Alcalá de Henares, 2000 (los interesados pueden solicitar una copia).
17. Dent TH, Sadler M. From guidance to practice: why NICE is not enough. BMJ. 2002;324:842-5.
18. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health. 2003;6 Suppl 1:1-9.
19. Drummond M, Jönsson B. Moving beyond the drug budget silo mentality in Europe. Value Health. 2003;6 Suppl 1:74-7.
20. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699-703.
21. Sacristán JA, Bolanos E, Hernández JM, Soto J, Galende I. Publication bias in health economic studies. Pharmacoeconomics. 1997;11:289-92.
22. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health. 2005;8:433-46.
23. Remak E, Hutton J, Jones M, Zagari M. Changes in cost-effectiveness over time. The case of epoetin alfa for renal replacement therapy patients in the UK. Eur J Health Econ. 2003;4:115-21.
24. Cohen J, Cabanilla L, Sosnov J. Role of follow-on drugs and indications on the WHO Essential Drug List. J Clin Pharm Ther. 2006;31:585-92.
25. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ. 2002;325:891-4.
26. Barrett A, Roques T, Small M, Smith RD. How much will herceptin really cost? BMJ. 2006;333:1118-20.
27. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298:221-4.